Clinical Trials
354
94 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1993
Active, not recruiting
44
12.4%
Completed
124
35.0%
Not yet recruiting
50
14.1%
Recruiting
44
12.4%
Suspended
2
0.6%
Terminated
8
2.3%
Unknown
77
21.8%
Withdrawn
5
1.4%
No approval data available
- King's College London & Guy's and St Thomas' PET Centre acquired two identical Biograph Vision Quadra total-body PET/CT scanners in late 2024 and early 2025, nicknamed the "twins." - The scanners' high sensitivity enables roughly half the radiation dose for patients and staff while scanning patients much faster, improving clinical efficiency. - The TOTEM study, with 1,400 patients recruited, is developing standardized total-body PET/CT protocols and has validated ultra-low-dose CT approaches within about six weeks. - An oncology trial using the [18F]FSPG tracer can predict head-and-neck cancer treatment outcomes within four weeks, versus 12 weeks for standard FDG scans.
- Claire Harrison received the European Hematology Association (EHA) 2026 Lifetime Achievement Award for her pioneering work in myeloproliferative neoplasms (MPN). - The landmark COMFORT-II Phase 3 trial established JAK inhibitors as the first effective therapy for myelofibrosis, rapidly improving symptoms, shrinking spleens, and extending survival. - Emerging targeted therapies, including a novel Type II JAK inhibitor, the anti-CALR monoclonal antibody INCA033989, and the SENTRY combination of selinexor plus ruxolitinib, signal a shift toward disease modification. - Harrison envisions the next decade moving MPN care from symptom control toward cure or minimal disease, with patients achieving good quality of life.
- A UK quality improvement project enrolled 126 older adults with cancer in a structured, age-adapted diabetes monitoring pathway during steroid-based systemic anti-cancer therapy. - The GOLD pathway produced no episodes of diabetic ketoacidosis or hyperosmolar hyperglycaemic syndrome and only three asymptomatic hypoglycaemic events across the programme. - Steroid regimens were modified for 24% of patients, and secondary referrals to specialist diabetes services fell from 36% in 2022 to 5% in 2025. - Separately, the 2026 ADA Standards of Care now recommend random glucose testing for checkpoint inhibitors and fasting glucose testing for PI3K-alpha and mTOR inhibitors.
- The Fleming Initiative and Cepheid have launched TRACE-CPE, a 30-month real-world study at two major London NHS Trusts to evaluate rapid molecular screening for carbapenemase-producing Enterobacterales (CPE). - The study compares rapid molecular diagnostics delivering results in approximately one hour against current culture-based screening that typically takes around 48 hours. - CPE is classified by the WHO as a critical-priority pathogen, and UKHSA data show acquired carbapenemase-producing organisms in England more than doubled between 2021 and 2023. - Findings aim to provide policymakers and clinicians with evidence on how rapid CPE screening should be deployed across the NHS and comparable health systems facing drug-resistant infections.
- Hypervision Surgical, a King's College London spinout, raised £17 million in Series A funding led by Heal Capital to accelerate commercial deployment of its hyperspectral imaging technology for surgery. - The company's Hyperspectral Intelligence® platform combines proprietary spectral sensing with AI analytics to provide real-time tissue insights beyond human vision during surgical procedures. - HYPERSNAP®, the first commercial system, is FDA-cleared and UK-certified for general surgery, with over 170 procedures completed across three UK NHS trusts. - The funding will support expansion to more UK, European, and US sites while advancing next-generation hyperspectral sensing technology co-developed with semiconductor leader imec.
- The landmark MACRO trial, the most extensive clinical investigation into chronic rhinosinusitis management to date, demonstrated that endoscopic sinus surgery significantly outperformed both clarithromycin antibiotics and placebo in improving quality of life scores at six months. - The study found no significant benefit from three-month clarithromycin treatment compared to placebo, challenging the routine use of long-term macrolide antibiotics in chronic rhinosinusitis patients. - Results support offering sinus surgery earlier in the treatment pathway without delay if symptoms don't respond to intranasal medications, potentially reducing unnecessary antibiotic prescriptions and associated resistance concerns.
- King's College London has secured £2.7 million in funding to develop OnchyMed, an innovative device that kills nail fungal infections in just 24 hours using sodium hydrogen sulphide technology. - The device addresses critical limitations of current treatments, which require 6-12 months of use due to poor nail penetration or cause liver and kidney toxicity with oral medications. - OnchyMed uses a novel approach where sodium hydrogen sulphide is delivered through a plastic nail cover, slowly releasing hydrogen sulphide gas that destroys fungus without entering the bloodstream. - If successful, the clinical trial will pave the way for the first clinically proven, fast-acting and non-invasive treatment for onychomycosis, which affects 10% of the global population and up to 50% of older adults.
- A phase 4 randomized controlled trial involving 514 patients found endoscopic sinus surgery significantly more effective than clarithromycin or placebo for treating chronic rhinosinusitis symptoms. - Surgery patients showed significantly lower SNOT-22 quality-of-life scores at 6 months compared to antibiotic treatment, with 87% reporting improved quality of life. - The three-month course of low-dose clarithromycin showed no significant benefit over placebo, challenging routine long-term antibiotic use in chronic rhinosinusitis management. - Results could streamline clinical pathways and reduce unnecessary antibiotic prescriptions while improving patient access to effective surgical intervention.
- Guy's and St Thomas' NHS Foundation Trust is expanding its Advanced Therapy Manufacturing Platform with two new ISO Class 7 cleanrooms to increase production capacity by up to 60%. - The facility expansion will accommodate a broader portfolio of advanced therapies including stem cell-derived photoreceptors and adherent cell products beyond its current regulatory T-cell immunotherapy work. - The project involves complex construction within an operational hospital environment while maintaining patient care and includes Grade A processing areas with enhanced material flow systems. - The expansion strengthens the UK's capabilities in GMP-compliant manufacturing of Investigational Medicinal Products for clinical trials in collaboration with King's College London.
- New studies presented at the American Thoracic Society Conference validate Brainomix's FDA-cleared e-Lung technology as a reliable tool for identifying progressive pulmonary fibrosis with greater sensitivity than conventional methods. - The validation studies utilized data from Boehringer Ingelheim's landmark INBUILD clinical trial, demonstrating e-Lung's ability to predict disease progression and patient outcomes independent of traditional CT imaging markers. - Brainomix's AI-powered imaging solution enables earlier treatment decisions and better patient prioritization, potentially addressing the critical diagnostic delay that affects pulmonary fibrosis patients who often wait up to two years for diagnosis.
